



LeanLife Health Inc.

380-580 Hornby Street
Vancouver, BC, V6C 3P6

NEWS RELEASE

LeanLife Signs Agreement to Begin Production

VANCOUVER, British Columbia, December 16, 2019: [LeanLife Health Inc.](#) (CSE: LLP) (the “Company”) a Company focused on proprietary plant-based food products is pleased to announce that the Company has signed an agreement with [Ecovatec Solutions Inc.](#) to begin production of the Company’s high-quality, shelf-stable Omega-3 food ingredient.

The Phase 1 Production Agreement permits LeanLife to use the advanced manufacturing facility of this local Canadian nutraceutical company. It follows a previous Testing Agreement with Ecovatec during which the Company validated its scalable, proprietary process and produced a certified product so incredibly high in purity and quality that it set a new near-impassable standard in the market.

The Agreement will allow LeanLife to begin production using its recently upgraded manufacturing equipment that was purchased to increase capacity and lower costs, thereby improving profit margins for the Company. Once the efficiencies of this improved production process materialize, the Company intends to enter into a further agreement with Ecovatec where they will mutually benefit from increased economies of scale.

LeanLife expects to commence production within the coming weeks, allowing it to build inventory and meet the anticipated significant customer demand for its products.

“The signing of this Agreement allows LeanLife to begin production and benefit from the resulting efficiencies of our upgraded equipment as we build inventory to meet forecasted customer demand in 2020,” said Stan Lis, CEO.

About LeanLife Health and the Omega-3 Market

LeanLife Health’s products are **long-term shelf-stable** extractions from flax seed, a plentiful **plant-based source of Omega-3**, that give them a significant advantage as an essential¹ fortified food ingredient.

Increased Omega-3 intake, especially with LeanLife’s higher Omega-3 to -6 ratio, has shown to have **significant health improvement impacts**.

¹ Omega-3 fatty acids are **essential** because the body cannot make them on its own and so they must be consumed from dietary sources.

LeanLife's mission is to provide a relatively **low-cost means of replacing the less healthy vegetable oil in food**, and **transform them into healthier versions**.

"Improving the quality of food without requiring people to change what they eat is the best way to ensure they eat healthier and benefit from an improved quality of life." – Stan Lis, CEO

LeanLife Health's industry leading and **proprietary Omega-3 product formulations** are of the **highest quality** and **contain no cholesterol**. Products are available in oil, emulsion and powder forms.

The products can be used as **food additives** or as **nutraceuticals** and have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

The **global Omega-3 market** reached USD \$33 Billion in 2016 and is **expected to reach upwards of USD \$57 Billion by 2025**, according to a report by Grand View Research, Inc.

For more information, please contact:

Stan Lis, CEO
604-764-0518
SLis@LeanLifeHealth.com

Forward Looking Information

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.